StockNews.com Initiates Coverage on Can-Fite BioPharma (NYSE:CANF)

Equities research analysts at StockNews.com started coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research note issued on Monday. The firm set a “hold” rating on the stock.

Can-Fite BioPharma Price Performance

Can-Fite BioPharma stock opened at $2.01 on Monday. The stock has a market cap of $7.12 million, a price-to-earnings ratio of -1.10 and a beta of 1.53. Can-Fite BioPharma has a 1 year low of $1.68 and a 1 year high of $3.33. The firm has a 50-day moving average of $2.16 and a two-hundred day moving average of $2.12.

Can-Fite BioPharma (NYSE:CANF) last released its quarterly earnings data on Thursday, March 28th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.04). The company had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $0.20 million. Can-Fite BioPharma had a negative net margin of 1,027.46% and a negative return on equity of 113.75%. Research analysts expect that Can-Fite BioPharma will post -0.03 earnings per share for the current year.

Institutional Investors Weigh In On Can-Fite BioPharma

A hedge fund recently bought a new stake in Can-Fite BioPharma stock. Schechter Investment Advisors LLC bought a new stake in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 20,077 shares of the company’s stock, valued at approximately $44,000. Schechter Investment Advisors LLC owned about 0.57% of Can-Fite BioPharma as of its most recent SEC filing. Hedge funds and other institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.